Risedronate Sodium
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00884 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 14 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | pseudo-von Willebrand disease | KG + DL |
| 2 | primary release disorder of platelets | KG + DL |
| 3 | HIV infectious disease | KG + DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | KG + DL |
| 5 | osteomesopyknosis | KG + DL |
| 6 | feline acquired immunodeficiency syndrome | KG + DL |
| 7 | simian immunodeficiency virus infection | KG + DL |
| 8 | Glanzmann thrombasthenia | KG + DL |
| 9 | Paget disease of bone | KG + DL |
| 10 | Paget disease of bone 2, early-onset | KG + DL |
| 11 | deficiency anemia | KG + DL |
| 12 | obsolete familial combined hyperlipidemia | KG + DL |
| 13 | vitamin B12- and folate-independent constitutional megaloblastic anemia | KG + DL |
| 14 | Plummer-Vinson syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.